Arvinas

NASDAQ ARVN
$32.43 0.0000 0.0000%
Today share price
USA
Sector: Healthcare Industry: Pharmaceuticals
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 25 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

1.98B
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

1.67B
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.

2.00
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.

61.10M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.

-21.21 %

Upcoming events Arvinas

All events
No upcoming events scheduled

Stock chart Arvinas

Stock analysis Arvinas

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.

More
-5.41 35.52
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.

More
3.00 13.63
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.

More
-4.22 17.42
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.

More
0.80 0.37
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.

More
-55.48 8.90

Price change Arvinas per year

19.68$ 108.47$
Min Max

Summary analysis Arvinas

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Arvinas

Revenue and net income Arvinas

All parameters

Stock news Arvinas

All news

Arvinas CFO Cassidy to Depart, Teel to Take Over on Interim Basis

Arvinas CFO Cassidy to Depart, Teel to Take Over on Interim Basis

Arvinas Shares Rise 13% on Securities-Purchase Agreement

Arvinas Shares Rise 13% on Securities-Purchase Agreement

Down 24% In A Month, Will Arvinas Stock Rebound?

Arvinas Shares Drop 14% After Analysts Downgrade, Price Target Cuts

Arvinas Shares Drop 14% After Analysts Downgrade, Price Target Cuts

Will Arvinas Stock Rebound After A 12% Drop In A Month?

Arvinas Inc Ranked Among Today’s Top Shorts As 10-Year Bond Yields Spike

Arvinas Inc Ranked Among Today’s Top Shorts As U.S. Deals With A Debt Ceiling Crisis

Arvinas Inc Ranked Among Today’s Top Shorts As Chinese Property Giant Evergrande Teeters On The Edge Of Defaulting On $300B Worth Of Debt

Arvinas Inc Ranked Among Today’s Top Shorts As Investors Await Upcoming Federal Reserve Meetings

Arvinas started at buy with $110 stock price target at BofA Securities

Arvinas Inc Ranked Among Today’s Top Shorts Amid Lower-Than-Expected New Jobs

Arvinas Inc Ranked Among Today’s Top Shorts Amid Pandemic-Era Low Jobless Claims

Arvinas Inc Ranked Among Today’s Top Shorts

Arvinas Inc Ranked Among Today’s Top Shorts

Pfizer to pay at least $1 billion to develop, commercialize Arvinas' investigational breast-cancer therapy

About company Arvinas

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Bayer AG, and Insilico Medicine, Inc. Arvinas, Inc. was incorporated in 2013 and is based in New Haven, Connecticut.
Address:
5 Science Park, New Haven, CT, United States, 06511
Company name: Arvinas
Issuer ticker: ARVN
ISIN: US04335A1051
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2018-09-27
Sector: Healthcare
Industry: Pharmaceuticals
Site: https://www.arvinas.com

On which stock exchange are Arvinas (ARVN) stocks traded?

Arvinas (ARVN) stocks are traded on NASDAQ.

What is the ticker of Arvinas stocks (ARVN)?

The stock ticker of Arvinas’s stocks or in other words, the code is ARVN. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does Arvinas (ARVN) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, Arvinas (ARVN) belongs to the «Healthcare» sector and the «Pharmaceuticals» industry.

In what currency are Arvinas (ARVN) stocks traded?

Arvinas (ARVN) stocks are traded on the NASDAQ exchange in dollars.

What is the price of Arvinas (ARVN) stocks today?

The current price of Arvinas stocks on 04.05.2024 is 32.43 dollars. per share.

What is the dynamics of Arvinas (ARVN) stocks from the beginning of the year?

Arvinas (ARVN) quotes have increased by -21.86% from the beginning of the year up to 32.43 dollars. per 1 stocks.

How much did Arvinas (ARVN) stocks increase in мае 2024?

This month Arvinas (ARVN) quotes have increased by -0.15% to 32.43 dollars. per share.

How much are Arvinas (ARVN) stocks worth?

Today, on October, 04.05.2024 Arvinas’s (ARVN) stocks cost 32.43 dollars..

What is the market capitalization of Arvinas (ARVN)?

Capitalization is the market value of Arvinas (ARVN) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 04.05.2024, the market capitalization of Arvinas (ARVN) is estimated at about 1981473000 dollars.